Clinical trial · Observational
Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
A Study Assessing Morbidity and Portal Circulation in Patients With Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with Myeloproliferative neoplasms are at particular risk for developing arterial and venous thrombosis, especially thrombosis in the splanchnic venous system. The patho-physiology and natural history of MPN related SVT is poorly understood and treatment algorithms vary greatly. This is of considerable importance since the morbidity and mortality in this group of patients is high. This study aims to observe patients with MPN related SVT over a period of five years to document their clinical progress. Methods of observation include clinical assessment, standard investigations and laboratory based research investigations
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloproliferative Disorders | Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Splanchnic Vein Thrombosis | — | UNRESOLVED | — |
| Splanchnic Venous Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| standard of care. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Composite end point comprising occurrence or change in morbidity or portal circulation over 18 months
- timeFrame
- 12-18 months from baseline
- description
- analysed by radiologic investigations and clinical progress
Secondary outcomes (1)
- measure
- 1. Occurrence or changes in morbidity over 5 years 2. Occurrence or changes in portal circulation over 5 years
- timeFrame
- 5 years from baseline
- description
- analysed by radiologic investigations and clinical progress
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. MPN with SVT between 3 weeks to 5 years of diagnosis of SVT: study arm 2. MPN with palpable splenomegaly or enlarged by Ultrasound: control arm Exclusion Criteria: Age \<18 years Patients with SVT without MPN
References
Publications (0)
Data not yet available